What Saudi Pharmaceutical Industries And Medical Appliances does

SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation) is a Saudi Joint-Stock pharmaceutical manufacturer established in 1986 with fully paid-up capital of SR 1.2 billion. The company operates 7 state-of-the-art manufacturing facilities across 4 countries, producing over 2.3 billion units annually, and holds the #1 position in Saudi Arabia's private pharmaceutical market. It markets a portfolio of more than 400 products spanning generic medicines, specialized medicines, vaccines (including the ENDOSA brand), biologics, and an ophthalmology pipeline in development, serving hospitals, pharmacies, and clinics across 21 strategic markets in the Middle East and North Africa.

The company's underlying technology stack centers on digital quality and manufacturing systems: an automated Quality Management System, a Manufacturing Execution System (MES), a Laboratory Information Management System (LIMS) integration, and predictive analytics for analytical processes and sample management. These systems are backed by ISO 9001 (quality), ISO 14001 (environmental), ISO 45001 (occupational health and safety), and ISO 17025 laboratory accreditation from the International Accreditation Service (IAS), supporting regulatory compliance across multiple jurisdictions.

Commercially, SPIMACO earns revenue through direct sales of branded and generic pharmaceutical products and through contract manufacturing and co-development arrangements with multinational pharmaceutical and biotechnology companies — disclosed CMO partners include Pfizer, Roche, Sanofi, MSD, Organon, Viatris, and CSL. Distribution is handled through a mix of global distributors/suppliers and direct relationships with healthcare providers, complemented by partnerships with Saudi government health initiatives. The most recent strategic move is the December 2025 launch of SPIMACO Bio, a subsidiary focused on biologic, genetic, and cell-based therapies that signals a planned shift up the value chain into advanced therapy modalities.

Name

Saudi Pharmaceutical Industries And Medical Appliances

Legal name

Saudi Pharmaceutical Industries & Medical Appliances Corporation

Website

https://spimaco.com.sa

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

SPIMACO is a Saudi publicly listed pharmaceutical manufacturer established in 1986, operating 7 plants across 4 countries producing 2.3 billion+ units annually. It serves hospitals, pharmacies, and clinics in 21 MENA markets with 400+ generic, specialized, vaccine, and biologic products, plus CMO partnerships with global pharma.

Ownership category

akta.pro rank

Headquarters

HQ city

Ar Riyadh

HQ country

Saudi Arabia

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

SPIMACO manufactures and supplies a portfolio of over 400 pharmaceutical products across multiple therapeutic categories, including generic medicines, specialized medicines, vaccines, biologics, and ophthalmology products, from 7 state-of-the-art manufacturing facilities in 4 countries with annual production capacity exceeding 2.3 billion units. The company also provides contract manufacturing services to leading global pharmaceutical and biotechnology partners and operates in 21 strategic markets across the Middle East and North Africa.

Product overview

SPIMACO (Saudi Pharmaceutical Industries And Medical Appliances Corporation) is a Saudi Joint-Stock pharmaceutical company with a fully paid-up capital of SR 1,200,000,000, established in 1986. The company operates 7 state-of-the-art manufacturing facilities across 4 countries with a production capacity exceeding 2.3 billion units annually. SPIMACO offers a diverse portfolio of over 400 products across multiple therapeutic categories, including Generic Medicines, Specialized Medicines, Vaccines (such as ENDOSA brand), Biologics, and Ophthalmology products. The company holds the #1 position in the private pharmaceutical market in Saudi Arabia and operates in 21 strategic markets across the Middle East and North Africa. Recently, SPIMACO announced the launch of SPIMACO Bio, a new subsidiary focused on biologic, genetic, and cell-based therapies.

Differentiator

Problem solved

Functional benefit

Brands

• SPIMACO Bio: A new subsidiary focused on biologic, genetic, and cell-based therapies, supporting advanced pharmaceutical manufacturing, knowledge transfer, and sustainable growth in the Kingdom

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Leading Hospitals & Healthcare ProviderscoreStrategic or Co-development PartnerSPIMACO collaborates with leading hospitals and healthcare providers globally to deliver innovative and life-changing medical solutions, ensuring that life-saving medications reach those who need them most.
• Pharmaceutical & Biotechnology CompaniescoreStrategic or Co-development PartnerSPIMACO partners with pharmaceutical and biotechnology companies including MSD, Organon, Pfizer, Roche, Sanofi, Viatris, CSL, and others for contract manufacturing and co-development opportunities.
• Government Health InitiativescoreStrategic or Co-development PartnerSPIMACO collaborates with government agencies on health initiatives to advance healthcare and make high-quality medicines accessible to the Saudi population.
• Global Distributors & SupplierscoreChannel Partner/ Reseller/ DistributorSPIMACO works with global distributors and suppliers to ensure pharmaceutical products reach international markets across the MENA region and beyond.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• EIPICO (Egyptian International Pharmaceutical Industries Company): Egypt-based generic pharmaceutical manufacturer with broad therapeutic coverage and MENA exports. Comparable regional generic manufacturer profile.
• Julphar (Gulf Pharmaceutical Industries): UAE-based generic pharmaceutical manufacturer with multi-country MENA manufacturing footprint and broad therapeutic portfolio. Highly comparable to SPIMACO in product mix, regional reach, and contract manufacturing activity.
• Tabuk Pharmaceuticals: Saudi Arabia-headquartered pharmaceutical manufacturer producing generics, branded, and specialty products for MENA markets. Direct domestic competitor and counterpart within the Saudi pharma localization landscape.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generic and specialty pharma manufacturer with strong MENA and US footprint. Comparable in generic manufacturing scale, therapeutic breadth, and regional market presence.
• Pharco Pharmaceuticals: Egypt's largest pharmaceutical manufacturer producing generics, specialty medicines, and biologics across MENA. Comparable in regional scale, generic-led portfolio, and emerging biologics orientation.
• Eva Pharma: Egyptian pharmaceutical manufacturer with broad generic and specialty portfolio exporting across MENA and emerging markets. Comparable generic manufacturing scale and regional distribution footprint.

Emerging players

• Cipla: India-headquartered global generic pharmaceutical manufacturer with active MENA presence through partnerships, manufacturing, and exports. Comparable in large-scale generic production and emerging biologics/specialty expansion.
• Aurobindo Pharma: India-based global generic manufacturer with significant MENA and emerging-market distribution. Comparable in generic scale, sterile manufacturing capabilities, and biologics/specialty expansion via subsidiaries.
• Dr. Reddy's Laboratories: India-headquartered global generic and biosimilar manufacturer with established MENA commercial presence. Comparable generic manufacturing scale and biosimilar/biologics pipeline ambitions.

Regional players

• Aspen Pharmacare: South African-headquartered specialty and generic pharmaceutical manufacturer with broad emerging-market presence. Comparable in geographic-diversified generic manufacturing and emerging-market commercial strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights3 records

Customer concentration

• Xtwitter.com/spimaco
• LinkedInlinkedin.com/company/spimaco

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Saudi Pharmaceutical Industries And Medical Appliances